# AENEAS2 (NCT04923906)

> Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04923906
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Conditions: Non-small Cell Lung Cancer
- Interventions: Aumolertinib; Placebo Aumolertinib
- Enrollment: 624
- Primary outcome: PFS (Progression Free Survival) assessed by IRC (Independent Review Committee)

## Indexed commentary on AENEAS2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aeneas2-nct04923906

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04923906", "email": "<work email>"}; the inbox owner confirms by the emailed link.